N@N

Mathew Blackman Maintained (TNDM) at Strong Buy with Increased Target to $55 on, May 22nd, 2024

Mathew Blackman of Stifel, Maintained "Tandem Diabetes Care, Inc." (TNDM) at Strong Buy with Increased Target from $45 to $55 on, May 22nd, 2024.

Mathew has made no other calls on TNDM in the last 4 months.

There are 6 other peers that have a rating on TNDM. Out of the 6 peers that are also analyzing TNDM, 2 agree with Mathew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Jeff Johnson of "Baird" Maintained at Hold with Increased Target to $36 on, Friday, May 3rd, 2024
• Rick Wise of "Stifel" Maintained at Hold with Increased Target to $24 on, Monday, February 5th, 2024

These are the ratings of the 4 analyists that currently disagree with Mathew

---

• Matt Miksic of "Barclays" Maintained at Buy with Increased Target to $55 on, Monday, May 6th, 2024
• Matt O'Brien of "Piper Sandler" Reiterated at Buy with Increased Target to $50 on, Friday, May 3rd, 2024
• Larry Biegelsen of "Wells Fargo" Maintained at Buy with Increased Target to $50 on, Friday, May 3rd, 2024
• Mike Kratky of "Leerink Partners" Upgraded from Hold to Buy and Increased Target to $45 on, Thursday, April 25th, 2024

Contributing Sources

---